2 hours Cytokinetics (NASDAQ:CYTK) Given Buy Rating at Needham & Company LLCMarketBeat
Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price objective on shares of Cytokinetics in a research report on Thursday.
XNeedham & Company LLC reiterated a “buy” rating and issued a $72.00 price objective on shares of Cytokinetics in a research report on Thursday.
X